Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Copaxone

 
National Institutes of Health

Related topics

Related topics

3 relations
1 ML glatiramer acetate 40 MG/ML Prefilled Syringe [Copaxone]

Broader (2)

Glatiramerglatiramer acetate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2003
Highly Cited
2003
Glatiramer Acetate (Copolymer-1, Copaxone) Promotes Th2 Cell Development and Increased IL-10 Production Through Modulation of Dendritic Cells1
Glatiramer acetate (GA; copolymer-1, Copaxone) suppresses the induction of experimental autoimmune encephalomyelitis and reduces… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 4
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Effect of glatiramer acetate (Copaxone) on CD4+CD25high T regulatory cells and their IL-10 production in multiple sclerosis
CD4(+)CD25(high) T regulatory (Tr) cells, representing high IL-2 receptor alpha chain expressing cells, have been shown to… Expand
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis.
Glatiramer acetate (GA; Copaxone) is a random copolymer of glutamic acid, lysine, alanine, and tyrosine that is used… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Comparison of glatiramer acetate (Copaxone®) and interferon β-1b (Betaferon®) in multiple sclerosis patients: an open-label 2-year follow-up
OBJECTIVE To compare the clinical efficacy, as expressed by relapse rate and disability accumulation, and safety profile of… Expand
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone®
Humoral and cellular immune responses were followed in multiple sclerosis patients treated with Copolymer 1 (Cop1, glatiramer… Expand
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells.
Copolymer-1 (Copaxone or COP) inhibits experimental allergic encephalomyelitis and has beneficial effects in multiple sclerosis… Expand
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Predictors of Adherence to Copaxone Therapy in Individuals with Relapsing‐Remitting Multiple Sclerosis*
&NA; The purpose of this study was to evaluate psychological, biophysical, and sociodemographic variables as predictors of… Expand
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.
We examined the effect of glatiramer acetate, a random copolymer of alanine, lysine, glutamic acid, and tyrosine, on antigen… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
1998
Highly Cited
1998
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability
When 251 relapsing-remitting patients with multiple sclerosis were randomized to receive daily subcutaneous injections of… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
Highly Cited
1998
Highly Cited
1998
Treatment of multiple sclerosis with Copolymer-1 (Copaxone®): implicating mechanisms of Th1 to Th2/Th3 immune-deviation
The synthetic polypeptide copolymer-1 (Cop-1; Copaxone; Glatiramer Acetate) has been recently approved as an effective treatment… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE